PE-22-28 vs Liraglutide
Side-by-side comparison of key properties, dosing, and research.
Cognitive Enhancement
PE-22-28GLP-1 / Weight Loss AgonistsFat Loss & Metabolic
Liraglutide- Summary
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- Liraglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It reduces appetite, slows gastric emptying, improves insulin secretion, and promotes weight loss of 5–10% in clinical trials.
- Half-Life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- ~13 hours (once-daily dosing)
- Admin Route
- SubQ, Intranasal
- SubQ
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- Start 0.6 mg, titrate to 3 mg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Promotes weight loss (5–10% average)
- Reduces appetite and caloric intake
- Improves blood glucose control (HbA1c reduction)
- Reduces cardiovascular events in T2DM (LEADER trial)
- Slows gastric emptying
- FDA-approved for T2DM and chronic weight management
- Cardioprotective effects shown in clinical trials
- May improve fatty liver (NAFLD/NASH)
- Side Effects
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Nausea (very common, especially initially)
- Vomiting
- Diarrhea or constipation
- Decreased appetite
- +5 more
- Stacks With
- —
- —